Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/673—Vitamin B group
  • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/007—Preparations for dry skin

Definitions

• the invention relates to skin moisturizing and conditioning compositions and methods. It is particularly concerned with the stimulation of ceramide production in the epidermis, leading to an increase in the level of these lipid materials in the stratum corneum of the skin, further leading to improved skin moisturization.
• the stratum corneum the outermost layer of the mammalian skin, contains intercellular lipids consisting predominately of ceramides, cholesterol and fatty acids. From studies involving lipid depletion of the stratum corneum by solvent extraction and from enzyme inhibition studies, ceramide, in particular, has been shown to be essential for the barrier function of the stratum corneum.
• the epidermis In normal skin, when there is disruption of the barrier function, the epidermis re-synthesizes the deficient lipids by inducing the expression or activation of the appropriate enzymes. However, under certain conditions, the skin's capacity for re- synthesis may be reduced. This is especially so in elderly subjects where the stratum corneum ceramide level is reportedly lower than that of younger subjects.
• compositions which activate and improve the normal synthesis of ceramide in mammalian skin.
• the consumer perceived benefits from such compositions are to be seen in the improvement of skin condition, namely eradication or reversal of skin aging including removal or age spots, keratoses, wrinkles, skin lines, blotches, blemishes, nodules, pigmented spots, coarse, rough and dry skin, together with improvements in skin barrier function leading to fewer 2
• ceramide synthesis precursors when used in combination with vitamin B 3 compounds such as niacinamide, provide improved ceramide synthesis.
• compositions which activate and increase the rate of ceramide synthesis It is therefore an object of the present invention to provide compositions which activate and increase the rate of ceramide synthesis.
• the present invention relates to skin moisturizing compositions comprising: a.) a safe and effective amount of a vitamin B 3 compound; and b.) from about 0.0001% to about 10% of a ceramide pathway intermediate or precursors thereof and mixtures thereof.
• the present invention also relates to methods of moisturizing skin by applying a safe and effective amount of the skin moisturizing composition. Unless otherwise indicated, all percentages and ratios used herein are by weight of the total composition. All weight percentages, unless otherwise indicated, are on an actives weight basis. All measurements made are at approximately 25°C, unless otherwise designated.
• safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive skin appearance or feel benefit, including independently the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
• the skin moisturizing compositions of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the 3
• compositions of the present invention comprise a safe and effective amount of a natural or synthetic vitamin B3 compound.
• the compositions of the present invention preferably comprise from about 0.01% to about 50%, more preferably from about 0.1% to about 40%, even more preferably from about 0.1% to about 20%, and still more preferably from about 1% to about 20%, most preferably from about 1% to about 10%, of the vitamin B3 compound .
• vitamin B3 compound means a compound having the formula: y N' wherein R is - CONH2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
• R is - CONH2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
• Exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
• Suitable esters of nicotinic acid include nicotinic acid esters of C1-C22, preferably Cj-C ⁇ . more preferably Cj-C ⁇ alcohols.
• the alcohols are suitably straight-chain or branched chain, cyclic or acyclic, saturated or unsaturated (including aromatic), and substituted or unsubstituted.
• the esters are preferably non- rubifacient.
• non-rubifacient means that the ester does not commonly yield a visible flushing response after application to the skin in the subject compositions (the majority of the general population would not experience a visible flushing response, although such compounds may cause vasodilation not visible to the naked eye).
• a nicotinic acid material which is rubifacient at higher doses could be used at a lower dose to reduce the rubifacient effect.
• nicotinic acid examples include tocopherol nicotinate and inositol hexanicotinate; tocopherol nicotinate is preferred.
• derivatives of the vitamin B3 compound are derivatives of niacinamide resulting from substitution of one or more of the amide group hydrogens.
• Nonlimiting examples of derivatives of niacinamide useful herein include nicotinyl amino acids, derived, for example, from the reaction of an activated nicotinic acid compound (e.g., nicotinic acid azide or nicotinyl chloride) with an amino acid, and nicotinyl alcohol esters of organic carboxylic acids (e.g., Cl - C18).
• Specific examples of such derivatives include nicotinuric acid and nicotinyl hydroxamic acid, which have the following chemical structures: nicotinuric acid: o o
• nicotinyl alcohol esters include nicotinyl alcohol esters of the carboxylic acids salicylic acid, acetic acid, glycolic acid, palmitic acid and the like.
• vitamin B3 compounds useful herein are 2- chloronicotinamide, 6-aminonicotinamide, 6-methylnicotinamide, n-methyl- nicotinamide, n,n-diethylnicotinamide, n-(hydroxymethyl)-nicotinamide, quinolinic acid imide, nicotinanilide, n-benzylnicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methyl isonicotinic acid, thionicotinamide, nialamide, l-(3-pyridylmethyl) urea, 2-mercaptonicotinic acid, nicomol, and niaprazine.
• Examples of the above vitamin B3 compounds are well known in the art and are commercially available from a number of sources, e.g., the Sigma Chemical 5
• vitamin B3 compounds may be used herein.
• Preferred vitamin B3 compounds may be used herein.
• B3 compounds are niacinamide and tocopherol nicotinate. Niacinamide is more preferred.
• salts, derivatives, and salt derivatives of niacinamide are preferably those having substantially the same efficacy as niacinamide in the methods of regulating skin condition described herein.
• Salts of the vitamin B3 compound are also useful herein.
• Nonlimiting examples of salts of the vitamin B3 compound useful herein include organic or inorganic salts, such as inorganic salts with anionic inorganic species (e.g., chloride, bromide, iodide, carbonate, preferably chloride), and organic carboxylic acid salts (including mono-, di- and tri- Cl - C18 carboxylic acid salts, e.g., acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such as acetate).
• anionic inorganic species e.g., chloride, bromide, iodide, carbonate, preferably chloride
• organic carboxylic acid salts including mono-, di- and tri- Cl - C18 carboxylic acid salts, e.g., acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such
• Wenner "The Reaction of L- Ascorbic and D-Isoascorbic Acid with Nicotinic Acid and Its Amide", J. Organic Chemistry, VOL. 14, 22-26 (1949), which is incorporated herein by reference. Wenner describes the synthesis of the ascorbic acid salt of niacinamide.
• the ring nitrogen of the vitamin B3 compound is substantially chemically free (e.g., unbound and/or unhindered), or after delivery to the skin becomes substantially chemically free ("chemically free” is hereinafter alternatively referred to as "uncomplexed”). More preferably, the vitamin B3 compound is essentially uncomplexed.
• such complex is preferably substantially reversible, more preferably essentially reversible, upon delivery of the composition to the skin.
• such complex should be substantially reversible at a pH of from about 5.0 to about 6.0. Such reversibility can be readily determined by one having ordinary skill in the art. 6
• the vitamin B3 compound is substantially uncomplexed in the composition prior to delivery to the skin.
• Exemplary approaches to minimizing or preventing the formation of undesirable complexes include omission of materials which form substantially irreversible or other complexes with the vitamin B3 compound, pH adjustment, ionic strength adjustment, the use of surfactants, and formulating wherein the vitamin B3 compound and materials which complex therewith are in different phases. Such approaches are well within the level of ordinary skill in the art.
• the vitamin B3 compound contains a limited amount of the salt form and is more preferably substantially free of salts of a vitamin B3 compound.
• the vitamin B3 compound contains less than about 50% of such salt, and is more preferably essentially free of the salt form.
• the vitamin B3 compound in the compositions hereof having a pH of from about 4 to about 7 typically contain less than about 50% of the salt form.
• the vitamin B3 compound may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
• the vitamin B3 compound is preferably substantially pure, more preferably essentially pure.
• vitamin B 3 compounds such as niacinamide serve as precursors to such enzyme co-factors as nicotinamide adenine nucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) and their reduced forms (NADH and NADPH).
• NAD nicotinamide adenine nucleotide
• NADP nicotinamide adenine dinucleotide phosphate
• NADH and NADPH reduced forms
• co-factors provide the metabolic energy for synthesis of cellular components.
• NADPH is a co-factor in the biosynthesis of fatty acids and sphinganine, two precursors to ceramides.
• NADPH is also believed to be an essential component of the cell for maintaining the cell's energy balance or reducing capacity, which is essential for normal cellular metabolic activity, including synthesis of biomolecules such as ceramides.
• Ceramide pathway intermediates or precursors Another essential component of the present invention are the ceramide pathway intermediates or precursors. Ceramide pathway intermediates or precursors are discussed in detail in U.S. Patents 5,578,641 to Simon et al. and U.S. Patent 5,610, 040 to Smeets et al., both of which are herein incorporated by reference. Without being limited by theory, it is believed the ceramide pathway intermediates or precursors serve to potentiate the ceramide synthesis properties of vitamin B 3 compounds to an extent greater than that of vitamin B 3 compounds alone
• Suitable ceramide pathway intermediates or precursors include, but are not limited to, serine, preferably L-serine; 3-dehydrosphinganine; sphinganine; sphingosine; fatty acid amides; palmitoyl co-enzyme A; their natural and synthetic analogs and derivatives; or combinations thereof.
• the ceramide pathway intermediates or precursors are preferably present at a concentration of from about 0.0001% to about 10%, more preferably from about 0.01% to about 5% , and most preferably from about 0.1% to about 2%.
• Ceramide pathway intermediates or precursors are commercially available from a number of sources, e.g., Sigma Chemical Co., St. Louis, MO.
• compositions of the present invention may, optionally, include ceramide synthesis co-factors.
• ceramide synthesis co-factors are molecules that are necessary for the biochemical reactions in ceramide synthesis to proceed but are not themselves converted into ceramides. Co- factors can often be rate-limiting in a biosynthetic process, particularly in older skin. Combining such co-factors with vitamin B 3 , thus, potentiates the ceramide synthesis properties of vitamin B 3 compounds.
• Non-limiting examples include pyridoxal, pyridoxine, pyridoxamine, riboflavin, pantothenic acid, co-enzyme A, acetyl co- enzyme A, flavin adenine dinucleotide (FAD), reduced FAD (FADH2), NAD, NADH, NADP, NADPH, their natural and synthetic analogs and derivatives, or mixtures thereof.
• the ceramide synthesis co-factors are preferably present at a concentration of from about 0.0001% to about 10%, more preferably from about 0.01% to about 5% , and most preferably from about 0.1% to about 2%.
• Ceramide synthesis co-factors useful in the present invention are commercially available from a number of sources, e.g., Sigma Chemical Co., St. Louis, MO.
• compositions of the present invention may also include enzyme inhibitors.
• Suitable enzyme inhibitors include neutral detergents (non-ionic surfactants), fatty acids, phosphatidyl choline, sphingomyelin, and N-oleylethanol amine.
• the enzyme inhibitors are preferably present at a concentration of from about 0.0001% to about 10%, more preferably from about 0.01% to about 5% , and most preferably from about 0.1% to about 2%.
• Enzyme inhibitors useful in the present invention are commercially available from a number of sources, e.g., Sigma Chemical Co., St. Louis, MO. Carrier
• compositions of the present invention may optionally contain a dermatologically acceptable carrier.
• dermatologically acceptable carrier means that the carrier is suitable for topical application to the skin, has good aesthetic properties, is compatible with the actives of the present invention and any other components, and will not cause any untoward safety or toxicity concerns.
• a safe and effective amount of carrier is from about 50% to about 99.99%), preferably from about 99.9% to about 80%, more preferably from about 98%o to about 90%, most preferably from about 95% to 90% of the composition.
• the carrier can be in a wide variety of forms.
• emulsion carriers including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil- in-water-in-silicone emulsions, are useful herein. These emulsions can cover a broad range of viscosities, e.g, from about 100 cps to about 200,000 cps. These emulsions can also be delivered in the form of sprays using either mechanical pump containers or pressurized aerosol containers using conventional propellants. These carriers can also be delivered in the form of a mousse.
• suitable topical carriers include anhydrous liquid solvents such as oils, alcohols, and silicones (e.g., mineral oil, ethanol, isopropanol, dimethicone, cyclomethicone, and the like); aqueous-based single phase liquid solvents (e.g., hydro-alcoholic solvent systems); and thickened versions of these anhydrous and aqueous-based single phase solvents (e.g., where the viscosity of the solvent has been increased to form a solid or semi-solid by the addition of appropriate gums, resins, waxes, polymers, salts, and the like).
• anhydrous liquid solvents such as oils, alcohols, and silicones (e.g., mineral oil, ethanol, isopropanol, dimethicone, cyclomethicone, and the like)
• aqueous-based single phase liquid solvents e.g., hydro-alcoholic solvent systems
• thickened versions of these anhydrous and aqueous-based single phase solvents e.
• topical carrier systems useful in the present invention are described in the following four references all of which are incorporated herein by reference in their entirety: "Sun Products Formulary” Cosmetics & Toiletries, vol. 105, pp. 122-139 (December 1990); “Sun Products Formulary", Cosmetics & Toiletries, vol. 102, pp. 117-136 (March 1987); U.S. Patent No. 4,960,764 to Figueroa et al., issued October 2, 1990; and U.S. Patent No. 4,254,105 to Fukuda et al., issued March 3, 1981. 10
• the carriers of the skin care compositions can comprise from about 50% to about 99% ⁇ by weight of the compositions of the present invention, preferably from about 75%) to about 99%, and most preferably from about 85% to about 95%.
• Preferred cosmetically and/or pharmaceutically acceptable topical carriers include hydro-alcoholic systems and oil-in-water emulsions.
• the carrier can comprise from about 0% to about 99% of ethanol, isopropanol, or mixtures thereof, and from about 1% to about 99% of water. More preferred is a carrier comprising from about 5% to about 60% of ethanol, isopropanol, or mixtures thereof, and from about 40% to about 95% of water.
• a carrier comprising from about 20% to about 50% of ethanol, isopropanol, or mixtures thereof, and from about 50% to about 80% of water.
• the carrier when the carrier is an oil-in-water emulsion, the carrier can include any of the common excipient ingredients for preparing these emulsions.
• suitable carriers are fount in U.S. Patent 5,605,894 to Blank et al., and in PCT application WO 97/39733, published October 30, 1997, to Oblong et al., both herein incorporated by reference in their entirety.
• the moisturizing compositions of the present invention may optionally comprise additional skin actives.
• skin actives include hydroxy acids such as salicylic acid; desquamatory agents such as zwitterionic surfactants; sunscreens such as 2-ethylhexyl-p-methoxycinnamate, 4,4'-t-butyl methoxydibenzoyl-methane, octocrylene, phenyl benzimidazole sulfonic acid; sunblocks such as zinc oxide and titanium dioxide; anti-inflammatory agents; anti- oxidants/radical scavengers such as tocopherol and esters thereof; metal chelators, especially iron chelators; retinoids such as retinol, retinyl palmitate, retinyl acetate, retinyl propionate, and retinal; N-acetyl-L-cysteine derivatives; benzofiiran derivatives; and skin protectants.
• Preferred skin actives include hydroxy acids such as salicylic acid, sunscreen , antioxidants and mixtures thereof. 11
• compositions of the present invention may also be included in the compositions of the present invention.
• Other suitable additives or skin actives are discussed in further
• compositions of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
• Non-limiting examples of the product form can be a gel, emulsion, lotion, cream, ointment, solution, liquid, etc.
• the methods of the present invention are useful for moisturizing mammalian skin (especially human skin, more especially human facial skin), especially the epidermis and more especially the stratum conreum of mammalian skin.
• the skin moisturization methods of the present invention involve topically applying to the skin a safe and effective amount of the skin moisturizing composition of the present invention.
• the amount of the composition which is applied, the frequency of application and the period of use will vary widely depending upon the level of vitamin B3 compound and/or other components of a given composition and the level of moisturization desired. 12
• the composition is chronically applied to the skin.
• chromenic topical application is meant continued topical application of the composition over an extended period during the subject's lifetime, preferably for a period of at least about one week, more preferably for a period of at least about two weeks, even more preferably for a period of at least one month, even more preferably for at least about three months, even more preferably for at least about six months, and more preferably still for at least about one year.
• benefits are obtainable after various maximum periods of use (e.g., five, ten or twenty years)
• it is preferred that chronic application continue throughout the subject's lifetime to maintain and/or increase the benefits achieved.
• applications would be on the order of one to four times per day over such extended periods, however application rates can be more than four times per day, especially for use on particularly dry skin-prone areas of the body such as the hands and legs.
• compositions of the present invention can be employed to provide a skin appearance and/or feel benefit.
• Quantities of the present compositions which are typically applied per application are, in mg composition/cm ⁇ skin, from about 0J mg/cm ⁇ to about 10 mg/cm ⁇ .
• a particularly useful application amount is about 2 mg/cm ⁇ .
• Regulating skin condition is preferably practiced by applying a composition in the form of a skin lotion, cream, gel, cosmetic, or the like which is intended to be left on the skin for some esthetic, prophylactic, therapeutic or other benefit (i.e., a "leave- on" composition). After applying the composition to the skin, it is preferably left on the skin for a period of at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, most preferably for at least several hours, e.g., up to about 12 hours.
• the patch can be occlusive, semi-occlusive or non-occlusive.
• the vitamin B3 compound composition can be contained within the patch or be applied to the skin prior to application of the patch.
• the patch can also include additional actives 13
• the patch is applied at night as a form of night therapy.
• a skin cream is prepared by conventional methods from the following components.
• Distearyldimonium chloride (Varisoft TA-100) 0.95
• Silicone fluid (Dow Corning DC Q2 - 1401; 0J5 cyclomethicone/dimethiconol - 50/50 blend)
• Blend the A phase components with a suitable mixer e.g., Tekmar model
• Example 2 An emulsion is prepared by conventional methods from the following components:
• Silicone fluid (Dow Corning DC 345) 15.0
• Silicone fluid (Goldschmidt Abil We09) 2.5
• a skin cream is prepared by conventional methods from the following components.
• Distearyldimonium chloride (Varisoft TA-100) 0.25
• Blend the A phase components with a suitable mixer e.g., Tekmar model RW20DZM
• a suitable mixer e.g., Tekmar model RW20DZM
• blend the C phase components and mill to obtain an acceptably smooth mixture e.g., using a Tekmar T50 Mill).
• composition to a subject's dry skin at the rate of 2 mg composition/cm ⁇ skin once or twice daily for a period of at least 3-6 months to improve moisturization.
• a skin cream is prepared by conventional methods from the following components.
• Methyl p-hydroxybenzoate (a.k.a. 0.20 methylparaben)
• Silicone fluid (Goldschmidt Abil We-09) 2.50
• Silicone fluid (Dow Corning DC 3225C) 2.50
• Blend the A phase components with a suitable mixer e.g., Tekmar model RW20DZM.
• composition to a subject's dry skin at the rate of 2 mg composition/cm ⁇ skin once or twice daily for a period of at least 3-6 months to improve moisturization.
• An alternative skin cream having reduced retinol levels can be prepared in the same manner from the above components wherein the retinol is added in an amount of 0.025%) (0.25%) of 10%) retinol in soybean oil), quo sine to 100% with water, the amounts of the other components being as shown.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Cosmetics (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22142083

Family Applications (1)

Country Status (6)

Cited By (7)

Families Citing this family (2)

Citations (6)

• 1999
  • 1999-03-12 EP EP99911342A patent/EP1063964A1/en not_active Withdrawn
  • 1999-03-12 AU AU30005/99A patent/AU3000599A/en not_active Abandoned
  • 1999-03-12 WO PCT/US1999/005409 patent/WO1999047114A1/en not_active Application Discontinuation
  • 1999-03-12 CN CN 99803778 patent/CN1292681A/zh active Pending
  • 1999-03-12 JP JP2000536354A patent/JP2002506803A/ja not_active Withdrawn
  • 1999-03-12 CA CA002322586A patent/CA2322586A1/en not_active Abandoned

Patent Citations (6)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events